@article{JTD13193,
author = {Stefan Schwarz and Peter Jaksch and Walter Klepetko and Konrad Hoetzenecker},
title = {Immunosuppression after lung transplantation: the search for the holy grail continues},
journal = {Journal of Thoracic Disease},
volume = {9},
number = {6},
year = {2017},
keywords = {},
abstract = {Immunosuppressive (IS) therapy after lung transplantation (LTx) remains a matter of controversy. Treatment regimens and concepts vary significantly between centers worldwide. Although there is a broad consensus on a triple IS therapy, protocols differ by the preferred calcineurin inhibitor (CNI) [cyclosporine A (CsA) vs. tacrolimus], cell cycle inhibitor [mycophenolate mofetil (MMF) vs. azathioprine] and induction therapy (basiliximab, ATG, alemtuzumab, no induction).},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/13193}
}